United States
Vertex Pharmaceuticals Incorporated Overview
Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing innovative therapies for cystic fibrosis (CF) and other serious diseases.
Key Products
- TRIKAFTA/KAFTRIO: For CF patients aged 2+ with at least one F508del mutation.
- ALYFTREK: Treats CF in patients aged 6+.
- SYMDEKO/SYMKEVI: For CF patients aged 6+.
- ORKAMBI: For CF patients aged 1+.
- KALYDECO: Treats CF in patients aged 1 month+ with ivacaftor.
Pipeline & Development
- CASGEVY: For sickle cell disease and transfusion-dependent beta thalassemia.
- JOURNAVX: Targets acute pain in adults.
- VX-522: CFTR mRNA therapeutic (Phase 1/2 trial).
- Inaxaplin: For APOL1-mediated kidney disease (Phase 2 trial).
- VX-880 & VX-264: Treatments for Type 1 Diabetes.
- VX-670: For myotonic dystrophy type 1.
- VX-407: Small molecule corrector for autosomal dominant polycystic kidney disease.
Distribution & Partnerships
Vertex sells its products through specialty pharmacies, distributors, retail pharmacies, hospitals, and clinics in the U.S. The company collaborates with:
- CRISPR Therapeutics AG
- Moderna, Inc.
- Entrada Therapeutics, Inc.
Founded: 1989 | Headquarters: Boston, Massachusetts
